RSS Feed Print Category View
AbbVie steps closer to FDA filing as first hep C PhIII delivers promising results
Posted: Monday, November 18, 2013 1:45 PM
Joined: 2/20/2013
Posts: 40

"AbbVie's all-oral "3D" regimen scored high sustained virological response rates among 631 treatment-naive patients after 12 weeks of treatment, hitting 96% for the treatment arm. The patients were all in the hard-to-treat genotype 1 category, with SVR rates of 95% and 98% for GT1a and GT1b patients. The discontinuation rate was low, only 0.6%, with a 1.7% relapse rate."

To read more, please visit: